Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

NCT04365400 is registered in ClinicalTrials.gov with Afimmune as lead sponsor.

NCT NCT04365400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04365400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
Lead sponsor
Afimmune
Phase
Phase 2
Overall status
Terminated
Start date
October 13, 2020
Completion date
May 3, 2022
Enrollment
233 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia, type 2 diabetes